

B3 SVB D3
concl
an E2 ubiquitin carrier protein, an E3 ubiquitin ligase, an unfoldase, a proteasome, a trafficking protein, or a retention protein.

B4 SVB D3
55. (Amended) The ligand profile of claim 4, wherein the multi-ligand binding receptor is a chaperone, a calnexin, a calreticulin, a mannosidase, a N-glycanase, a BIP, a grp94, a grp96, an E2 ubiquitin carrier protein, an E3 ubiquitin ligase, an unfoldase, a proteasome, a trafficking protein, or a retention protein.

B5 SVB D3
60. (Amended) The ligand profile of claim 5, wherein the multi-ligand binding receptor is a chaperone, a calnexin, a calreticulin, a mannosidase, a N-glycanase, a BIP, a grp94, a grp96, an E2 ubiquitin carrier protein, an E3 ubiquitin ligase, an unfoldase, a proteasome, a trafficking protein, or a retention protein.

B6
64. (Amended) The method of claim 10, wherein the selected type of multi-ligand binding receptor is a chaperone, a calnexin, a calreticulin, a mannosidase, a N-glycanase, a BIP, a grp94, a grp96, an E2 ubiquitin carrier protein, an E3 ubiquitin ligase, an unfoldase, a proteasome, a trafficking protein, or a retention protein.

B7
69. (Amended) The method of claim 14, wherein the first type of multi-ligand binding receptor is a chaperone, a calnexin, a calreticulin, a mannosidase, a N-glycanase, a BIP, a grp94, a grp96, an E2 ubiquitin carrier protein, an E3 ubiquitin ligase, an unfoldase, a proteasome, a trafficking protein, or a retention protein.

B8
75. (Amended) The method of claim 17, wherein the given type of multi-ligand binding receptor is a chaperone, a calnexin, a calreticulin, a mannosidase, a N-glycanase, a BIP, a grp94, a grp96, an E2 ubiquitin carrier protein, an E3 ubiquitin ligase, an unfoldase, a proteasome, a trafficking protein, or a retention protein.

B9
80. (Amended) The set of ligand profiles of claim 21, wherein the at least one type of multi-ligand binding receptor is a chaperone, a calnexin, a calreticulin, a mannosidase, a N-

glycanase, a BIP, a grp94, a grp96, an E2 ubiquitin carrier protein, an E3 ubiquitin ligase, an unfoldase, a proteasome, a trafficking protein, or a retention protein.

89
concl

Add new claims 84-92.

B10
~~--84. (New) The ligand profile of claim 8, wherein the multi-ligand binding receptor is a chaperone selected from the group consisting of a chaperonin, hsp60, hsp65, hsp70, hsp90, hsp25, and hsp100.~~

~~85. (New) The ligand profile of claim 45, wherein the multi-ligand binding receptor is a chaperone selected from the group consisting of a chaperonin, hsp60, hsp65, hsp70, hsp90, hsp25, and hsp100.~~

~~86. (New) The ligand profile of claim 50, wherein the multi-ligand binding receptor is a chaperone selected from the group consisting of a chaperonin, hsp60, hsp65, hsp70, hsp90, hsp25, and hsp100.~~

SUB D3)
~~87. (New) The ligand profile of claim 55, wherein the multi-ligand binding receptor is a chaperone selected from the group consisting of a chaperonin, hsp60, hsp65, hsp70, hsp90, hsp25, and hsp100.~~

~~88. (New) The ligand profile of claim 60, wherein the multi-ligand binding receptor is a chaperone selected from the group consisting of a chaperonin, hsp60, hsp65, hsp70, hsp90, hsp25, and hsp100.~~

~~89. (New) The method of claim 64, wherein the selected type of multi-ligand binding receptor is a chaperone selected from the group consisting of a chaperonin, hsp60, hsp65, hsp70, hsp90, hsp25, and hsp100.~~

90. (New) The method of claim 69, wherein the first type of multi-ligand binding receptor is a chaperone selected from the group consisting of a chaperonin, hsp60, hsp65, hsp70, hsp90, hsp25, and hsp100.

91. (New) The method of claim 75, wherein the given type of multi-ligand binding receptor is a chaperone selected from the group consisting of a chaperonin, hsp60, hsp65, hsp70, hsp90, hsp25, and hsp100.

92. (New) The set of ligand profiles of claim 80, wherein the at least one type multi-ligand binding receptor is a chaperone selected from the group consisting of a chaperonin, hsp60, hsp65, hsp70, hsp90, hsp25, and hsp100.--

B10
cond